Scotiabank Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its price objective cut by stock analysts at Scotiabank from $3.15 to $1.40 in a report issued on Friday,Benzinga reports. The brokerage presently has a “sector outperform” rating on the biotechnology company’s stock. Scotiabank’s price target points to a potential upside of 381.43% from the stock’s previous […]
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its price objective cut by stock analysts at Scotiabank from $3.15 to $1.40 in a report issued on Friday,Benzinga reports. The brokerage presently has a “sector outperform” rating on the biotechnology company’s stock. Scotiabank’s price target points to a potential upside of 381.43% from the stock’s previous […]
